![Dan Crooks, Ph.D.](/sites/default/files/styles/sixth_1_1/public/staff-profile-images/2023-06-23-NCI-UOB-Dan%20Crooks%20R4.jpg?h=17b80029&itok=Tf0GgxM6)
Daniel Crooks, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10 CRC. Rm. 1W-5940
- Bethesda, MD 20892
- 240-858-3700
- crooksda@mail.nih.gov
RESEARCH SUMMARY
Dr. Crooks' current research is focused on the characterization of altered tumor metabolism in hereditary cancers, including those caused by mutations in the Krebs cycle enzymes fumarate hydratase (HLRCC) and succinate dehydrogenase (SDH-RCC), as well as renal tumors associated with Birt-Hogg-Dubé and von Hippel-Lindau syndromes. The approach is to utilize stable isotope-resolved metabolomics, genomics, transcriptomic, proteomic and molecular approaches to identify targetable metabolic alterations in human tumors and tumor cells that can offer new therapeutic possibilities for these unique patient populations. Dr. Crooks is also the Acting Director of the CCR Clinical Cancer Metabolism Facility located in NIH Building 10 for the conduct of metabolomics studies and metabolic imaging, with a focus on targeted analysis of human tissue samples, isotope-resolved metabolomics studies of patient-derived tissues and cells, and pre-clinical and human metabolic imaging technologies.
Areas of Expertise
![Dan Crooks, Ph.D.](/sites/default/files/styles/sixth_1_1/public/staff-profile-images/2023-06-23-NCI-UOB-Dan%20Crooks%20R4.jpg?h=17b80029&itok=Tf0GgxM6)